Certificate of Analysis
Third Party Tested
Molecular Profile
Compound
Tirzepatide
Batch #
GLS250510-LC1091806
Formula
C225H348N48O68
Mol Wt
4813 g/mol
CAS
2023788-19-2
Latest
ISO 17025
8× Testing
99.63%
Purity
VariantTirzepatide
COA ##11577
Labeled50mg
Validation KeyAXISBIOTECH
Tested12/15/25
Full QC Panel - 8× tested
✓
Purity (HPLC) - 99.63%
✓
Net Peptide Content - 50mg
✓
Identity (HPLC) - Tirzepatide
✓
Fentanyl Screen - Not Detected
✓
HPLC Conformity mean - >98%
✓
ISO/IEC 17025 Accredited
Storage Requirements
Stability Information
Lyophilized (powder)
−20°C long-term
2–8°C
Reconstituted
Recommended condition
Light protection
Store away from light
Sealed lyophilized vials are heat-stable; refrigerating or freezing sealed vials is optional. 2–8°C applies to reconstituted solutions.
Peer-Reviewed Literature
Research & References
Research and reference material related to this compound.
01
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2)
02
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1)
03
Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)
04
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes
05
MOUNJARO (tirzepatide) — FDA Approval for Type 2 Diabetes Mellitus
Safety & Regulatory Compliance Warning
These products are intended solely for laboratory research and analytical applications. They have not been evaluated by the U.S. Food and Drug Administration (FDA) and are not approved for therapeutic use, diagnosis, treatment, or prevention of disease. Under no circumstances should these materials be used for human or animal consumption.
